Welcome to our dedicated page for Gossamer Bio SEC filings (Ticker: GOSS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Gossamer Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Gossamer Bio's regulatory disclosures and financial reporting.
Gossamer Bio, Inc. obtained stockholder approval at a July 14, 2026 special meeting for several major capital structure actions. Holders approved, under Nasdaq Listing Rule 5635(d), the potential issuance of Common Stock upon conversion of up to $72.0 million in aggregate principal amount of newly issued 7.50% Convertible Senior Secured First Lien Notes due 2030, related make-whole payments in stock, and the exercise of 135,789,000 newly issued Purchase Warrants, which together could exceed 20% of shares outstanding before the Exchange Offer.
Stockholders also approved an amended and restated 2019 Incentive Award Plan, increasing the shares available for equity compensation, and a Charter amendment raising authorized Common Stock from 700,000,000 to 4,000,000,000 to support potential issuances under the notes, warrants and plan. In addition, they approved 30 alternate Charter amendments to permit a reverse stock split of outstanding Common Stock and a proportionate reduction in authorized Common Stock and total authorized capital stock.
D. E. Shaw–affiliated entities report an 8.3% beneficial stake in Gossamer Bio, Inc. common stock. The group may be deemed to beneficially own 40,630,726 Common Shares out of 488,846,722 shares outstanding as of June 5, 2026.
Valence holds 38,362,468 shares, or about 7.8% of the class. Cogence holds 1,878,827 shares, or about 0.4%, and funds under DESIM management hold 389,431 shares, or about 0.1%, including 1,200 shares in DSIF. Various D. E. Shaw entities have shared voting and dispositive power, while none owns shares directly and David E. Shaw disclaims beneficial ownership.
Gossamer Bio, Inc. filed an 8-K to share the finalized conversion and warrant terms for its 7.50% Convertible Senior Secured First Lien Notes due 2030. Each $1,000 principal amount of these notes will initially convert into 5,347.5936 shares of common stock, implying a conversion price of about $0.19 per share. The company also set the initial exercise price of related Purchase Warrants at $0.34 per whole share. These figures were derived from a $0.17 Reference Price calculated over a seven trading-day period beginning on June 22, 2026.
Gossamer Bio announced the final results of its exchange offer for its 5.00% Convertible Senior Notes due 2027. Holders tendered $181,052,000 in aggregate principal amount of these notes, leaving $18,948,000 outstanding after the transaction.
Tendering holders received a pro rata mix of up to $72.0 million of new 7.50% Convertible Senior Secured First Lien Notes due 2030, up to 317,647,058 common shares or prefunded warrants, and, for early tendering eligible holders, additional warrants. Following early settlement on June 4, 2026, Gossamer entered into a supplemental indenture that eliminated substantially all restrictive covenants and certain events of default in the prior indenture for the exchanged notes.
D. E. Shaw and related entities report a large stake in Gossamer Bio, Inc. following a debt-for-equity exchange. They report beneficial ownership of 46,485,295 common shares, equal to 9.5% of Gossamer’s outstanding stock as of June 5, 2026, held through Valence, Cogence and funds managed by DESIM.
On June 4, 2026, the reporting group acquired 48,107,644 new shares plus new 7.50% Convertible Senior Secured First Lien Notes due 2030 and purchase warrants in an exchange of existing 5.00% convertible notes. In total, the issuer issued $65,174,000 of new convertible notes, 254,150,441 new shares, 33,402,727 prefunded warrants and 135,789,000 purchase warrants in the early settlement.
The new notes pay 7.50% interest, mature in 2030 with a springing 2027 maturity if more than $4.0 million of old notes remain, and include conversion features subject to stockholder approval and a 4.99%–9.99% beneficial ownership cap. The purchase warrants are exercisable from December 3, 2026 to June 4, 2031 with similar ownership limits. D. E. Shaw’s entities also hold short positions referencing 3,732,304 shares.
Gossamer Bio, Inc. reporting persons filed a joint Schedule 13G disclosing shared beneficial ownership positions in the issuer's Common Stock. The filing shows 37,665,073 shares reported for DeepCurrents/related parties (representing 7.7%) and 27,646,139 shares attributed to DCIG Capital Master Fund (representing 5.7%). The filing cites June 5, 2026 as the reference date for 488,846,722 shares outstanding used to calculate percentages.
The statement clarifies record ownership: the Fund and a separately managed account are direct owners, DeepCurrents is the investment manager, DCIG GP is the general partner, and Kai Zheng is a managing member. Each Reporting Person disclaims beneficial ownership of shares held directly by the others.
683 Capital Management, 683 Capital Partners and Ari Zweiman report beneficial ownership totaling 49,868,571 shares of Gossamer Bio. The figure includes 39,504,484 shares of Common Stock, 9,102,055 currently exercisable warrants, and 1,262,032 shares issuable upon conversion of convertible notes.
The filing states this position represents approximately 9.99% of Common Stock on a basis that uses 488,846,722 shares outstanding as of June 5, 2026 plus the currently exercisable warrants and specified convertible-note issuances; the calculation is subject to a 9.99% beneficial ownership limitation in the relevant indenture.
Gossamer Bio has called a virtual special stockholder meeting to approve several major capital structure changes tied to a recent exchange of its $200.0 million 5.00% convertible notes.
The company has already exchanged $181,052,000 of these notes (90.526%) for $65,174,000 of new 7.50% secured convertible notes due 2030, 254,150,441 new shares, 33,402,727 prefunded warrants and 135,789,000 purchase warrants, leaving $18,948,000 of old notes outstanding.
Stockholders are being asked to approve potential share issuances on conversion of up to $72.0 million of new notes and exercise of 135,789,000 purchase warrants (exceeding Nasdaq’s 20% dilution threshold), a large increase in authorized common shares from 700,000,000 to 4,000,000,000, an expanded equity incentive plan, authority for a reverse stock split, and the ability to adjourn the meeting if needed. The company discloses that these transactions have already caused substantial dilution and could ultimately give former noteholders up to 868,235,293 shares, or approximately 78.7% of outstanding common stock under full conversion assumptions.
Gossamer Bio disclosed that Context Capital Management and related reporting persons collectively hold 48,835,788 shares of common stock, representing 9.9% of the class. The filing states the percentage is calculated using 488,846,722 shares outstanding as of June 5, 2026. The report clarifies the ownership cap in an agreement is 9.99% and shows shared voting and dispositive power over the reported shares.
Gossamer Bio, Inc. director John D. Quisel received a grant of stock options covering 115,000 shares of common stock as board compensation. The options have an exercise price of $0.178 per share and expire on June 3, 2036.
The entire option grant becomes fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, conditioned on his continued board service. This is a routine non-employee director award rather than an open-market share purchase or sale.